Stimufend® (pegfilgrastim), a biosimilar of Amgen’s Neulasta®, has been approved for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with significant incidence of febrile neutropenia.

• Fresenius Kabi, a global health care company, announced FDA approval of its pegfilgrastim biosimilar, Stimufend, for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
• The company expects to launch the product in a prefilled syringe early next year and in an on- body injector.